Literature DB >> 14592962

Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells.

Alexandra Berger1, Roland Lang, Kerstin Moritz, Radmila Santic, Anton Hermann, Wolfgang Sperl, Barbara Kofler.   

Abstract

Recently we have shown that galanin binding significantly correlates with survival in neuroblastoma patients, indicating a possible modulatory role of galanin receptors in neuroblastic tumor biology. However, the molecular mechanisms beyond this correlation have not been elucidated. Here, the cellular effects on activation of specific galanin receptor subtypes in human SH-SY5Y neuroblastoma cells were analyzed using a tetracycline-controlled expression system. Pharmacological studies confirmed the inducible expression of high affinity binding sites for galanin in SH-SY5Y cells transfected with the galanin receptors GalR1 (SY5Y/GalR1) and GalR2 (SY5Y/GalR2). Microphysiometry revealed that both receptor subtypes were able to mediate an intracellular signal upon galanin application. Interestingly, induction of receptor expression and treatment with 100 nm galanin resulted in a dramatic decrease in cell viability in SY5Y/GalR2 cells (93 +/- 3%) compared with a less pronounced effect in SY5Y/GalR1 cells (19 +/- 10%). The antiproliferative potency of galanin was 100-fold higher in SY5Y/GalR2 (50% effective concentration, 1.1 nm) than in SY5Y/GalR1 cells (50% effective concentration, 190 nm). Furthermore, activation of receptor expression and exposure to galanin resulted in apparent morphological changes indicative of apoptosis in SY5Y/GalR2 cells only. Induction of cell death by the apoptotic process was confirmed by poly-(ADP-ribose)-polymerase cleavage, caspase-3 activation, and the typical laddering of DNA. This study indicates that a high level of GalR2 expression is able to inhibit cell proliferation and induce apoptosis in neuroblastoma cells and therefore identifies GalR2 as a possible target for pharmacological intervention in neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592962     DOI: 10.1210/en.2003-0649

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2).

Authors:  R Tofighi; B Joseph; S Xia; Z-Q D Xu; B Hamberger; T Hökfelt; S Ceccatelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

2.  Epigenetic inactivation of galanin receptor 1 in head and neck cancer.

Authors:  Kiyoshi Misawa; Yo Ueda; Takeharu Kanazawa; Yuki Misawa; Ilwhan Jang; John Chadwick Brenner; Tetsuya Ogawa; Satoru Takebayashi; Reidar A Grenman; James G Herman; Hiroyuki Mineta; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

3.  An assembly of galanin-galanin receptor signaling network.

Authors:  Lathika Gopalakrishnan; Oishi Chatterjee; Chinmayi Raj; Deepshika Pullimamidi; Jayshree Advani; Anita Mahadevan; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2020-11-02       Impact factor: 5.782

4.  Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene.

Authors:  Radmila Santic; Katrin Fenninger; Kerstin Graf; Rainer Schneider; Cornelia Hauser-Kronberger; Freimut H Schilling; Per Kogner; Manfred Ratschek; Neil Jones; Wolfgang Sperl; Barbara Kofler
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

5.  Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.

Authors:  Kiyoshi Misawa; Yuki Misawa; Takeharu Kanazawa; Daiki Mochizuki; Atsushi Imai; Shiori Endo; Thomas E Carey; Hiroyuki Mineta
Journal:  Clin Exp Metastasis       Date:  2015-11-16       Impact factor: 5.150

6.  Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.

Authors:  Takeharu Kanazawa; Pavan K Kommareddi; Toshihide Iwashita; Bhavna Kumar; Kiyoshi Misawa; Yuki Misawa; Ilwhan Jang; Thankam S Nair; Yukiko Iino; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

7.  GABAergic terminals are a source of galanin to modulate cholinergic neuron development in the neonatal forebrain.

Authors:  Erik Keimpema; Kang Zheng; Swapnali Shantaram Barde; Paul Berghuis; Márton B Dobszay; Robert Schnell; Jan Mulder; Paul G M Luiten; Zhiqing David Xu; Johan Runesson; Ülo Langel; Bai Lu; Tomas Hökfelt; Tibor Harkany
Journal:  Cereb Cortex       Date:  2013-07-29       Impact factor: 5.357

8.  Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer.

Authors:  Kiyoshi Misawa; Takeharu Kanazawa; Yuki Misawa; Takayuki Uehara; Atsushi Imai; Goro Takahashi; Satoru Takebayashi; Andrew Cole; Thomas E Carey; Hiroyuki Mineta
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

9.  Alarin is a vasoactive peptide.

Authors:  Radmila Santic; Sabine M Schmidhuber; Roland Lang; Isabella Rauch; Elena Voglas; Nicole Eberhard; Johann W Bauer; Susan D Brain; Barbara Kofler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

Review 10.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.